We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Nayanacare is a mobile and pc app that allows individual customers to make the right choice of care services and carers quick and easy. Care suppliers can reduce costs by using Nayanacare as a dedicated marketing platform and take advantage of the platforms business management capabilities.
days to go: Expired investment: £76,030
Stablepharma invents a disruptive solution that can eliminate waste and supply life-saving vaccines without refrigeration. It is a patented invention that allows vaccines to be stored for years and transported without refrigeration whilst adhering with the protocols established by the WHO. Its current project plan comprises the Tetanus vaccine processed by Clinical Trials in Humans. The success of this project will significantly enhance the value of the invention and allow it to set up a pilot scale production in the $36 bn human vaccine market.
days to go: Expired investment: £1,310,090
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £532,311
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Please watch the video for more information
days to go: Expired investment: £607,175
OVD Development Ltd. owns IP rights for fluorescent products used for ophthalmic surgery, which is basically a new approach to viscoelastic medium (OVD). The goal of OVD Development Ltd. is to complete the CE marking process. Till 2017, it estimates to be worth $560 million with an expected 11.6% average annual growth in the global market.
days to go: Expired investment: £82,300
Please watch the video for more information
days to go: Expired investment: £257,501
MGB Biopharma is tackling the worldwide threat of antimicrobial resistance.   The company is in the process of clinical study and designing a new class of antibiotic.  They are looking for investment to start phase 2 of the study with 70% being supported by a grant.
days to go: Expired investment: £1,309,621
Tourniglo is a company that has come up with a unique two in one emergency tourniquet with a built-in torch. The innovation was driven by an identified need within the emergency services to provide an immediately available light source in dim-lighted areas when undertaking a patient or casualty eye examination as well as for military and close protection staff who might need to inject intravenous medication in rural areas. The global tourniquet systems market is expected to reach half a billion US dollars by 2025. The company aims to launch the production of its first product. Additionally, Tourniglo has been featured on the BBC website and has won various medals at international events, including a 'Gold Medal' at the World Invention Awards. The company requires investment to set-up manufacturing, packaging and distribution, and grow sales for the first year of commercialisation.
days to go: Expired investment: £21,414
Providing convenient and affordable healthcare to patients either at home or their workplace. Practitioners can visit patients and offer a range of medical treatments including vaccinations, testing, physiotherapy and primary care. Qured have been highly successful in London and are growing at an alarming rate, ready to help the whole of the UK.
days to go: Expired investment: £763,160
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph